Which has higher earnings and valuation, PCSA or CLRB?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$9.29 N/A Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A

Is PCSA or CLRB more profitable?

Heatwurx's return on equity of -281.31% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% Cellectar Biosciences N/A -365.85% -164.45%

Is PCSA or TVRD more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% Tvardi Therapeutics N/A -64.17% -43.90%

Do analysts rate PCSA or VYNE?

Heatwurx currently has a consensus price target of $25.00, indicating a potential upside of 928.81%. Given Heatwurx's stronger consensus rating and higher possible upside, equities research analysts plainly believe Heatwurx is more favorable than VYNE Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 VYNE Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PCSA or VYNE more profitable?

Heatwurx has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% VYNE Therapeutics -4,726.21% -70.42% -63.46%

Is PCSA or DARE more profitable?

Heatwurx has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Heatwurx's return on equity of -281.31% beat Dare Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% Dare Bioscience -803.80% -512.31% -36.20%

Is LPCN or PCSA more profitable?

Heatwurx has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -755.39% -64.75% -57.62% Heatwurx N/A -281.31% -200.80%

Heatwurx (PCSA) Competitors

$2.43 -0.07 (-2.80%)

Closing price 04:00 PM Eastern

Extended Trading

$2.44 +0.01 (+0.62%)

As of 07:59 PM Eastern

Compare

PCSA vs. CLRB, TVRD, VYNE, DARE, and LPCN

Should you buy Heatwurx stock or one of its competitors? Heatwurx's main competitors and comparable companies include Cellectar Biosciences (CLRB), Tvardi Therapeutics (TVRD), VYNE Therapeutics (VYNE), Dare Bioscience (DARE), and Lipocine (LPCN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Heatwurx compare to Cellectar Biosciences?

Heatwurx (NASDAQ:PCSA) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends, institutional ownership and media sentiment.

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Heatwurx's return on equity of -281.31% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
Cellectar Biosciences	N/A	-365.85%	-164.45%

Heatwurx presently has a consensus price target of $25.00, indicating a potential upside of 928.81%. Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 323.08%. Given Heatwurx's higher possible upside, equities analysts plainly believe Heatwurx is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Heatwurx has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A

In the previous week, Cellectar Biosciences had 5 more articles in the media than Heatwurx. MarketBeat recorded 8 mentions for Cellectar Biosciences and 3 mentions for Heatwurx. Cellectar Biosciences' average media sentiment score of 1.15 beat Heatwurx's score of 0.44 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Heatwurx	Neutral
Cellectar Biosciences	Positive

Summary

Cellectar Biosciences beats Heatwurx on 7 of the 13 factors compared between the two stocks.

How does Heatwurx compare to Tvardi Therapeutics?

Heatwurx (NASDAQ:PCSA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

In the previous week, Tvardi Therapeutics had 2 more articles in the media than Heatwurx. MarketBeat recorded 5 mentions for Tvardi Therapeutics and 3 mentions for Heatwurx. Heatwurx's average media sentiment score of 0.44 beat Tvardi Therapeutics' score of -0.03 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Neutral
Tvardi Therapeutics	Neutral

Heatwurx has higher earnings, but lower revenue than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
Tvardi Therapeutics	$7.14M	2.50	-$18.21M	-$3.10	N/A

Heatwurx currently has a consensus price target of $25.00, indicating a potential upside of 928.81%. Tvardi Therapeutics has a consensus price target of $18.00, indicating a potential upside of 847.37%. Given Heatwurx's higher probable upside, equities research analysts clearly believe Heatwurx is more favorable than Tvardi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Heatwurx has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Tvardi Therapeutics' return on equity of -64.17% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Summary

Tvardi Therapeutics beats Heatwurx on 9 of the 14 factors compared between the two stocks.

How does Heatwurx compare to VYNE Therapeutics?

Heatwurx (NASDAQ:PCSA) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

Heatwurx has higher earnings, but lower revenue than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
VYNE Therapeutics	$570K	33.29	-$26.48M	-$0.38	N/A

Heatwurx currently has a consensus price target of $25.00, indicating a potential upside of 928.81%. Given Heatwurx's stronger consensus rating and higher possible upside, equities research analysts plainly believe Heatwurx is more favorable than VYNE Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
VYNE Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

91.9% of Heatwurx shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 3.5% of Heatwurx shares are held by company insiders. Comparatively, 3.0% of VYNE Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Heatwurx has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%

Heatwurx has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, meaning that its share price is 100% more volatile than the broader market.

In the previous week, Heatwurx had 2 more articles in the media than VYNE Therapeutics. MarketBeat recorded 3 mentions for Heatwurx and 1 mentions for VYNE Therapeutics. Heatwurx's average media sentiment score of 0.44 beat VYNE Therapeutics' score of -3.00 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Neutral
VYNE Therapeutics	Very Negative

Summary

Heatwurx beats VYNE Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Heatwurx compare to Dare Bioscience?

Heatwurx (NASDAQ:PCSA) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Heatwurx has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. Heatwurx's return on equity of -281.31% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
Dare Bioscience	-803.80%	-512.31%	-36.20%

In the previous week, Dare Bioscience had 7 more articles in the media than Heatwurx. MarketBeat recorded 10 mentions for Dare Bioscience and 3 mentions for Heatwurx. Dare Bioscience's average media sentiment score of 0.78 beat Heatwurx's score of 0.44 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Heatwurx	Neutral
Dare Bioscience	Positive

Dare Bioscience has higher revenue and earnings than Heatwurx. Dare Bioscience is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
Dare Bioscience	$1.03M	13.62	-$13.40M	-$0.95	N/A

Heatwurx presently has a consensus target price of $25.00, indicating a potential upside of 928.81%. Dare Bioscience has a consensus target price of $10.00, indicating a potential upside of 975.27%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Heatwurx has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Dare Bioscience beats Heatwurx on 11 of the 14 factors compared between the two stocks.

How does Heatwurx compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Heatwurx (NASDAQ:PCSA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 4.7% of Lipocine shares are held by insiders. Comparatively, 3.5% of Heatwurx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lipocine has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Heatwurx has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

In the previous week, Heatwurx had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Heatwurx and 2 mentions for Lipocine. Lipocine's average media sentiment score of 1.31 beat Heatwurx's score of 0.44 indicating that Lipocine is being referred to more favorably in the media.

Company	Overall Sentiment
Lipocine	Positive
Heatwurx	Neutral

Lipocine currently has a consensus target price of $15.00, suggesting a potential upside of 610.90%. Heatwurx has a consensus target price of $25.00, suggesting a potential upside of 928.81%. Given Heatwurx's stronger consensus rating and higher probable upside, analysts plainly believe Heatwurx is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lipocine has higher revenue and earnings than Heatwurx. Lipocine is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	8.78	-$9.63M	-$1.79	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

Heatwurx has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Heatwurx	N/A	-281.31%	-200.80%

Summary

Lipocine and Heatwurx tied by winning 7 of the 14 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCSA vs. The Competition

Export

Metric	Heatwurx	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.92M	$11.73B	$6.98B	$13.04B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	N/A	781.47	269.86	25.30
Price / Sales	N/A	750.79	601.81	101.06
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	0.99	10.81	13.08	6.33
Net Income	-$13.56M	$2.77B	$3.45B	$347.70M
7 Day Performance	-5.45%	0.17%	1.12%	1.07%
1 Month Performance	6.11%	0.35%	1.79%	1.03%
1 Year Performance	-55.86%	161.52%	67.69%	20.77%

Heatwurx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCSA Heatwurx	3.0075 of 5 stars	$2.43 -2.8%	$25.00 +928.8%	-56.1%	$6.92M	N/A	N/A	20	Earnings Report Short Interest Increase
CLRB Cellectar Biosciences	3.5128 of 5 stars	$2.57 +1.6%	$11.00 +328.0%	-44.6%	$20.22M	N/A	N/A	10	News Coverage Positive News Earnings Report
TVRD Tvardi Therapeutics	3.6011 of 5 stars	$2.10 flat	$18.00 +757.1%	-92.5%	$19.70M	$7.14M	N/A	80	News Coverage Earnings Report Short Interest Decrease Gap Up
VYNE VYNE Therapeutics	0.2347 of 5 stars	$28.33 -0.8%	N/A	+63.0%	$18.98M	$570K	N/A	30	Negative News Earnings Report Gap Down High Trading Volume
DARE Dare Bioscience	2.4945 of 5 stars	$1.22 -1.6%	$10.00 +719.7%	-35.1%	$18.70M	$1.03M	N/A	30	News Coverage Earnings Report Gap Up Trading Halted

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCSA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heatwurx (PCSA) Competitors

PCSA vs. CLRB, TVRD, VYNE, DARE, and LPCN

How does Heatwurx compare to Cellectar Biosciences?

Summary

How does Heatwurx compare to Tvardi Therapeutics?

Summary

How does Heatwurx compare to VYNE Therapeutics?

Summary

How does Heatwurx compare to Dare Bioscience?

Summary

How does Heatwurx compare to Lipocine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heatwurx (PCSA) Competitors

PCSA vs. CLRB, TVRD, VYNE, DARE, and LPCN

How does Heatwurx compare to Cellectar Biosciences?

Do institutionals and insiders have more ownership in PCSA or CLRB?

Is PCSA or CLRB more profitable?

Do analysts recommend PCSA or CLRB?

Which has more volatility and risk, PCSA or CLRB?

Which has higher earnings and valuation, PCSA or CLRB?

Does the media prefer PCSA or CLRB?

Summary

How does Heatwurx compare to Tvardi Therapeutics?

Does the media prefer PCSA or TVRD?

Which has stronger earnings and valuation, PCSA or TVRD?

Do analysts rate PCSA or TVRD?

Do insiders & institutionals have more ownership in PCSA or TVRD?

Which has more risk & volatility, PCSA or TVRD?

Is PCSA or TVRD more profitable?

Summary

How does Heatwurx compare to VYNE Therapeutics?

Which has better valuation & earnings, PCSA or VYNE?

Do analysts rate PCSA or VYNE?

Do institutionals and insiders believe in PCSA or VYNE?

Is PCSA or VYNE more profitable?

Which has more risk & volatility, PCSA or VYNE?

Does the media refer more to PCSA or VYNE?

Summary

How does Heatwurx compare to Dare Bioscience?

Is PCSA or DARE more profitable?

Does the media refer more to PCSA or DARE?

Which has stronger earnings and valuation, PCSA or DARE?

Do analysts prefer PCSA or DARE?

Which has more risk and volatility, PCSA or DARE?

Do insiders and institutionals believe in PCSA or DARE?

Summary

How does Heatwurx compare to Lipocine?

Do insiders and institutionals believe in LPCN or PCSA?

Which has more risk and volatility, LPCN or PCSA?

Does the media favor LPCN or PCSA?

Do analysts prefer LPCN or PCSA?

Which has stronger earnings & valuation, LPCN or PCSA?

Is LPCN or PCSA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools